<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02869971</url>
  </required_header>
  <id_info>
    <org_study_id>P150917</org_study_id>
    <secondary_id>PHRC-15-521</secondary_id>
    <secondary_id>2016-A00247-44</secondary_id>
    <nct_id>NCT02869971</nct_id>
  </id_info>
  <brief_title>Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia</brief_title>
  <acronym>PARTEM</acronym>
  <official_title>Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to compare the 9-month effect on lower urinary tract&#xD;
      symptoms (LUTS) of Prostatic Artery Embolization (PAE) using Embosphere® versus Standard&#xD;
      Combined Therapy (alpha-blockers plus 5 alpha-reductase inhibitors) in patients with&#xD;
      symptomatic BPH who failed after a first line medical treatment with alpha-blockers.&#xD;
&#xD;
      The secondary objectives of this study are to:&#xD;
&#xD;
        -  Estimate the impact of the 2 strategies on benign prostatic hyperplasia specific Health&#xD;
           Status (i.e. urinary and sexual signs and symptoms) at 3, 9, 18, and 24 months, as well&#xD;
           as the side effects of the 2 strategies;&#xD;
&#xD;
        -  Report the safety of PAE;&#xD;
&#xD;
        -  Evaluate patient's adherence to medical treatment;&#xD;
&#xD;
        -  Analyse the costs of each strategy and report the incremental efficiency (incremental&#xD;
           cost utility ratio) of prostatic artery embolization compared to medical treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Benign Prostatic Hyperplasia (BPH) is the primary cause of lower urinary tract symptoms&#xD;
      (LUTS) and affects &gt; 50% of men &gt;60 years. Moderate to severe symptoms prevalence is around&#xD;
      14% in France, and the proportion of men with moderate to severe symptoms doubles with each&#xD;
      decade of age. The first-line treatment of bothersome BPH-related LUTS is medical therapy as&#xD;
      recommended by French and European guidelines. 5α reductase inhibitors (5-ARI) can be&#xD;
      combined with alpha-blockers and allow reduction of the size of the prostate and LUTS&#xD;
      improvement. The severity of symptoms is usually assessed using the International prostate&#xD;
      symptom score (IPSS) which is the standard questionnaire for the objective assessment of&#xD;
      LUTS.&#xD;
&#xD;
      Recently, Prostatic Artery Embolization (PAE) has been proposed to treat symptomatic BPH with&#xD;
      good safety and efficacy in single-centre studies (12-point IPSS reduction at 3 months&#xD;
      maintained up to one year. In a randomized trial comparing PAE versus transurethral resection&#xD;
      of prostate (TURP), Gao reported a 16-point IPSS reduction at 6 months, and an increase in&#xD;
      the maximum urinary flow rate (Qmax) comprised between 12 ml/s and 24 ml/s at 6 months and up&#xD;
      to 21 ml/s at 2 years. The complication rate is low (a few cases of bladder ulcer have been&#xD;
      published) and the patient generally experiences mild post-embolization symptoms for few&#xD;
      days.&#xD;
&#xD;
      PAE can be performed during a one-day hospitalisation and could be very attractive to&#xD;
      patients which have insufficient benefit of medical treatment or who have side effects&#xD;
      affecting their quality of life. The most used device for PAE is Embosphere® (Merit Medical).&#xD;
      It bears the European CE (Conforme aux Exigences) marking for this specific indication and&#xD;
      approximately 500 patients have been treated with it worldwide. Nonetheless, no big&#xD;
      randomized study has proven its efficacy compared with best medical treatment. A study&#xD;
      comparing PAE using Embosphere® and surgery (TURP) is currently enrolling patients; no&#xD;
      patients could be included in France because men with BPH refused to be potentially assigned&#xD;
      the surgical arm.&#xD;
&#xD;
      To properly evaluate PAE, the investigators designed the PARTEM trial, which has received the&#xD;
      support of both the Societe Francaise de Radiologie (French society of radiology) and of the&#xD;
      Association Francaise d'Urologie (French association of urology).&#xD;
&#xD;
      PARTEM will compare prospectively the benefit of PAE using Embosphere® to the benefit of&#xD;
      combined medical treatment (Combodart®: Dutasteride 0.5mg Tamsulosin 0.4mg) at 9 months with&#xD;
      an extended follow up at 24 months in order to evaluate the stability of results in both&#xD;
      groups.&#xD;
&#xD;
      The investigators plan a multicentre, prospective, randomized, open label, parallel trial,&#xD;
      comparing PAE to Combined Therapy (CT: alpha-blockers + 5-ARI treatment). Treatments will be&#xD;
      allocated by minimization with a 1:1 ratio, based on study centre, IPSS score&#xD;
      (moderate/severe) and prostate volume (&lt; 80 g/≥80 g).&#xD;
&#xD;
      This study is designed to demonstrate the superiority of PAE to decrease LUTS compared to&#xD;
      best medical treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Actual">December 3, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in IPSS score</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>3, 9, 18, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPSS</measure>
    <time_frame>3, 18, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qmax</measure>
    <time_frame>3, 9, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function (IIEF) score</measure>
    <time_frame>3, 9, 18, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prostate volume</measure>
    <time_frame>3, 9, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate-Specific Antigen (PSA) level</measure>
    <time_frame>3, 9, 18, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>3, 9, 18, 24 months</time_frame>
    <description>assessed by IPSS/Quality of Life (QoL) form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment units' account</measure>
    <time_frame>3, 9 months</time_frame>
    <description>adherence to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to treatment questionnaire</measure>
    <time_frame>3, 9 months</time_frame>
    <description>adherence to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of PAE</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of surgical treatment</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of medication</measure>
    <time_frame>3, 9, 18, 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prostatic Arteries Embolization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combodart® : dutasteride 0.5 mg/tamsulosin 0.4 mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Embosphere® (Prostatic Arteries Embolization)</intervention_name>
    <description>Prostatic Arteries Embolization with 300-500 µm trisacryl microspheres</description>
    <arm_group_label>Embolization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug therapy</intervention_name>
    <description>Combodart (dutasteride 0.5 mg/tamsulosin 0.4 mg)</description>
    <arm_group_label>Combined Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men aged&gt;= 50 and &lt;=85 years AND&#xD;
&#xD;
          -  Moderate to severe LUTS defined as IPSS &gt; 11, and QoL &gt; 3 AND&#xD;
&#xD;
          -  No improvement after an alpha blocker treatment line (Tamsulosin 0.4 mg p.d. during 1&#xD;
             month) AND&#xD;
&#xD;
          -  Prostatic volume &gt;=50 ml AND&#xD;
&#xD;
          -  Affiliated to a French health insurance system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe allergy to iodine contrast agent&#xD;
&#xD;
          -  Treatment with 5-ARI on the last 6 months&#xD;
&#xD;
          -  Suspected prostate cancer requiring specific management&#xD;
&#xD;
          -  On-going prostatitis&#xD;
&#xD;
          -  On-going urinary retention&#xD;
&#xD;
          -  On-going acute urinary infection&#xD;
&#xD;
          -  Acontractile detrusor&#xD;
&#xD;
          -  Neurogenic lower urinary tract dysfunction&#xD;
&#xD;
          -  Urethral stenosis&#xD;
&#xD;
          -  Bladder diverticulum&#xD;
&#xD;
          -  Bladder stone with surgical indication&#xD;
&#xD;
          -  Patient refusing PAE&#xD;
&#xD;
          -  Creatinine clearance &lt;40 ml/min&#xD;
&#xD;
          -  Severe liver failure&#xD;
&#xD;
          -  Contra-indication to alpha-blockers&#xD;
&#xD;
          -  Hypersensitivity to dutasteride, other 5-alpha reductase inhibitors, tamsulosin&#xD;
             (including case of tamsulosin induced angioedema), soya, peanut or one of the&#xD;
             excipients&#xD;
&#xD;
          -  Hypersensitivity to gelatin or collagen&#xD;
&#xD;
          -  Patients ineligible for pelvic angiography&#xD;
&#xD;
          -  History of orthostatic hypotension&#xD;
&#xD;
          -  Patient unable or unwilling to provide written informed consent&#xD;
&#xD;
          -  Patient under legal protection&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Sapoval, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Lyon hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <state>Auvergne-Rhone-Alpes</state>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon centre hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Benite</city>
        <state>Auvergne-Rhone-Alpes</state>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <state>Bretagne</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier hopital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <state>Languedoc-Roussillon-Midi-Pyrenees</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier hopital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <state>Languedoc-Roussillon-Midi-Pyrenees</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux groupe hospitalier Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <state>Nouvelle-Aquitaine</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <state>Nouvelle-Aquitaine</state>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM hopital la Conception</name>
      <address>
        <city>Marseille</city>
        <state>Provence-Alpes-Cote d'Azur</state>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <state>Provence-Alpes-Cote d'Azur</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP hopital Henri-Mondor</name>
      <address>
        <city>Creteil</city>
        <state>Île-de-France</state>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <state>Île-de-France</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP hopital Cochin</name>
      <address>
        <city>Paris</city>
        <state>Île-de-France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <state>Île-de-France</state>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>August 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2016</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostatic artery embolization</keyword>
  <keyword>Combined Therapy</keyword>
  <keyword>IPSS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

